文献速递鼻科

嗜酸性慢性鼻窦炎的诊断标准:比较分析与新型评分系统

Diagnostic criteria for eosinophilic chronic rhinosinusitis: Comparative analysis and novel scoring system.
PubMed 文献 · Int Forum Allergy Rhinol · 2024-07-22

该回顾性观察研究纳入2021年1月至2022年12月在单一三级中心因慢性鼻窦炎接受内镜鼻窦手术的640例患者,比较新型评分系统与既往诊断标准预测组织嗜酸性粒细胞计数≥70/高倍视野的嗜酸性慢性鼻窦炎(ECRS)的准确性。新型评分的AUC在估计组为0.753,验证组为0.729,全数据集20折交叉验证为0.661。作者提出「血嗜酸性粒细胞百分比+前筛窦Lund-Mackay总分+2(若存在鼻息肉)>7」可用于诊断ECRS。

要点

  • 新型评分=AUC估计组0.753、验证组0.729、20折交叉验证0.661。
  • 作者提出评分>7可可靠诊断ECRS。
  • 评分可辅助术前决策口服激素和靶向2型炎症的生物制剂。

核心结论

  • 作者提出一种纳入三个参数的新型评分系统:「新型评分=血嗜酸性粒细胞百分比+前筛窦Lund-Mackay总分+2(若存在鼻息肉)」,评分>7可可靠用于诊断ECRS。

研究设计与样本

  • 回顾性观察研究,纳入2021年1月至2022年12月在单一三级中心因慢性鼻窦炎接受内镜鼻窦手术的640例患者。
  • 患者被随机分为估计组(n=430)和验证组(n=210)。

主要发现

  • 新型评分的AUC在估计组为0.753(95%CI 0.670-0.835),在验证组为0.729(95%CI 0.629-0.830)。
  • 新型评分在全数据集20折交叉验证中的AUC为0.661(95%CI 0.584-0.738)。

关键数值与推荐

  • 以组织嗜酸性粒细胞计数≥70/高倍视野定义ECRS。
  • 新型评分=血嗜酸性粒细胞百分比+前筛窦Lund-Mackay总分+2(若存在鼻息肉),评分>7可可靠诊断ECRS。

临床怎么用

  • 作者认为该评分系统可辅助在手术干预前决定是否使用口服激素和靶向2型炎症的生物制剂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate identification of eosinophilic chronic rhinosinusitis is essentialg because its treatment and prognosis substantially differ from other subtypes. METHODS: This retrospective observational study included 640 patients who underwent endoscopic sinus surgery for chronic rhinosinusitis in a single tertiary center from January 2021 to December 2022. Receiver operating characteristic curves were generated to compare accuracy, sensitivity, specificity of the novel scoring system, and previous diagnostic criteria (Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis, European Forum for Research and Education in Allergy and Airway Diseases, European Position Paper on Rhinosinusitis and Nasal Polyps, and Sakuma et al.) for predicting eosinophilic chronic rhinosinusitis (ECRS) by tissue eosinophil count ≥70 per high power field. RESULTS: Patients were randomly divided into estimation (n = 430) and validation (n = 210) groups. The area under the receiver operating characteristic curve for the novel score was 0.753 (95% confidence interval [CI], 0.670-0.835) in the estimation group, 0.729 (0.629-0.830) in the validation group, and 0.661 (0.584-0.738) in the 20-fold cross-validation with the entire dataset. CONCLUSIONS: We propose a novel scoring system that incorporates three key parameters: "novel score = blood eosinophil (%) + total Lund-Mackay score of anterior ethmoid sinuses + 2 if nasal polyp present" greater than 7 can be reliably used for diagnosing ECRS. This system can facilitate decision-making processes regarding the administration of oral steroids and biologics targeting type 2 inflammation prior to surgical intervention.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Lee JY, Kim DH, Kim SW, et al. Diagnostic criteria for eosinophilic chronic rhinosinusitis: Comparative analysis and novel scoring system. Int Forum Allergy Rhinol. 2024. PMID: 39039646. doi:10.1002/alr.23416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。